Zsa Zsa Weerts

Cost-effectiveness of peppermint oil in IBS 209 8 Supplementary Tables Table S8.1 Proportion of patients with incomplete data by treatment allocation (ITT population). Placebo Small-intestinal release Peppermint oil N =64 N =62 Utility , N (%) Baseline T = 4 weeks T = 8 weeks 0 1 (1.6) 3 (4.7) 0 1 (1.6) 4 (6.5) Absenteeism , N (%) Baseline T = 4 weeks T = 8 weeks 0 1 (1.6) 3 (4.7) 0 1 (1.6) 4 (6.5) Presenteeism , N (%) Baseline T = 4 weeks T = 8 weeks T = 6 months 34 (53.1) 32 (50.0) 30 (48.4) 15 (23.4) 34 (54.8) 33 (53.2) 27 (43.5) 16 (25.8) Resource use , N (%) Baseline T = 8 weeks 0 3 (4.7) 0 4 (6.5) Table S8.2 Utilities and IBS-QoL scores per measurement moment (ITT-population. Placebo N =64 Small-intestinal release Peppermint oil N =62 Estimated means (SE) Estimated means (SE) Treatment effect (95% CI) P- value IBS quality of life score µ Baseline T = 4 weeks T = 8 weeks 70.47 (2.47) 73.66 (2.47) 75.01 (2.50) 68.75 (2.56) 72.87 (2.56) 75.85 (2.59) - 0.93 (-1.75; 3.60) 2.56 (-0.17; 5.29)- - 0.495 0.066 EQ-5D-5L ♮ Baseline T = 4 weeks T = 8 weeks 0.70 (0.03) 0.71 (0.03) 0.72 (0.03) 0.71 (0.03) 0.76 (0.03) 0.77 (0.03) - 0.04 (-0.01; 0.10) 0.04 (-0.01; 0.10) - 0.110 0.131 Treatment effect is the corrected difference in change from baseline between small-intestinal release peppermint oil and placebo, obtained from linear mixed modelling. P -value is level of significance of comparison between small-intestinal release peppermint oil and placebo. The treatment period consisted of eight weeks. µ Assessed using the IBS-QoL questionnaire. ♮ Assessed using the EuroQoL-5D (EQ-5D-5L) questionnaire.